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ABSTRACT
Objective To assess whether receiving a negative test
result at primary care based stepwise diabetes screening
results in false reassurance.
Design Parallel group cohort study embedded in a
randomised controlled trial.
Setting 15 practices (10 screening, 5 control) in the
ADDITION (Cambridge) trial.
Participants 5334 adults (aged 40-69) in the top quarter
for risk of having undiagnosed type 2 diabetes (964
controls and 4370 screening attenders).
Main outcome measures Perceived personal and
comparative risk of diabetes, intentions for behavioural
change, and self rated health measured after an initial
random blood glucose test and at 3-6 and 12-15 months
later (equivalent time points for controls).
Results A linear mixed effects model with control for
clustering by practice found no significant differences
between controls and people who screened negative for
diabetes in perceived personal risk, behavioural
intentions, or self rated health after the first appointment
or at 3-6 months or 12-15 months later. After the initial
test, people who screened negative reported significantly
(but slightly) lower perceived comparative risk (mean
difference −0.16, 95% confidence interval −0.30 to
−0.02; P=0.04) than the control group at the equivalent
time point; no differences were evident at 3-6 and
12-15 months.
Conclusions A negative test result at diabetes screening
does not seem to promote false reassurance,whether this
is expressed as lower perceived risk, lower intentions for
health related behavioural change, or higher self rated
health. Implementing a widespread programme of
primary care based stepwise screening for type2diabetes
is unlikely to cause an adverse shift in the population
distribution of plasma glucose and cardiovascular risk
resulting froman increase in unhealthy behaviours arising
from false reassurance among people who screen
negative.
Trial registration Current controlled trials
ISRCTN99175498.
INTRODUCTION
A national screening programme for cardiovascular
risk factors, including testing for type 2 diabetes, is
now being implemented.1 Justification for screening
programmes requires that the overall benefit of test-
ing—resulting mainly from early intervention in peo-
ple at risk—is greater than anypossible harmsof testing
the population. Whether this criterion is met for
screening for diabetes remains uncertain.2 3
Research evaluating the benefits of screening and
early intervention among people at risk of diabetes
has shown that stepwise screening identifies those
with a raised and potentially modifiable risk of coron-
ary heart disease.4 5 Studies have also examined the
direct harms to people attending screening and
shown limited evidence of adverse psychological
effects associated with diabetes screening programmes
in terms of increased anxiety and depression.6-9 In part,
this may be because stepwise screening in the context
of primary care offers an opportunity for psychological
adjustment as participants progress through the screen-
ing programme.10
Research describing the potential harms of screen-
ing has focused on people who screen positive,11 12 and
few studies have considered the potential indirect
harms to people attending screening. In particular,
research has yet to examine whether people with a
negative test result at diabetes screeningmay be falsely
reassured.13 14 This is important because the potential
adverse effects of false reassurance include decreased
intentions for behavioural change,3 13 justification of
unhealthy behaviours through a “certificate of health”
effect,15 16 and delays in seeking medical help.17
As the vastmajority (90%) of peoplewho take part in
diabetes screening programmes test negative, even a
small harm to those who test negative (for example,
through a reduction in intentions to be physically
active) may outweigh a large benefit to the few people
who test positive. The population distribution of
plasma glucose in the United Kingdom is approxi-
mately normal and shows a positive linear relation to
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cardiovascular risk.18-20 Consequently, if a substantial
proportion of people who take part in screening for
diabetes are falsely reassured and show a reduction in
intentions to improve their diet or increase their level
of physical activity as a result of screening, then the net
effect of screening could be to move the population
distribution of plasma glucose and cardiovascular risk
in the wrong direction.
The potential problemof false reassurance in cardio-
vascular screening has been described as “an uninten-
tional adverse effect of screening . . . evident when
people erroneously conclude that their screening result
means that they are at less risk than they actually are.”21
Someevidence shows false reassurance associatedwith
screening for cardiovascular risk factors,16 22 but no stu-
dies to date have examined false reassurance when
quantified as a reduction in intentions for behavioural
change or a decrease in perceived risk in the context of
diabetes screening.13 14 In particular, a need exists to
assess false reassurance among people with risk factors
for diabetes who receive a negative test result at
screening.23 This is especially timely given the Depart-
ment of Health’s decision to include screening for dia-
betes in the national vascular risk assessment
programme.1
We aimed to investigate false reassurance in the
short term (after the initial appointment) and the med-
ium to long term (three to six months and
12-15 months later) among participants who test nega-
tive for diabetes in a primary care based stepwise
screening programme. We hypothesised that those
who test negative for diabetes would report lower per-
ceived risk of developing diabetes, lower intentions for
behavioural change, and higher self reported health
than a (non-screening) control group.
METHODS
Participants were registered at 15 primary care prac-
tices included in the Cambridge arm of the Anglo-
Danish-Dutch Study of Intensive Treatment in People
with Screen Detected Diabetes in Primary Care (the
ADDITION trial). A comprehensive description of
the screening procedure and recruitment methods for
this study has been published.4 7 The ADDITION
(Cambridge) trial aims to evaluate the effectiveness
and cost effectiveness of a stepwise screening strategy
for type 2 diabetes and intensive multifactorial treat-
ment for people with screen detected diabetes in pri-
mary care.4 The primary outcomes in this trial are
modelled cardiovascular risk at one year and cardio-
vascular mortality and morbidity at five years after
diagnosis of diabetes.
Embedded within the ADDITION (Cambridge)
trial was a substudy that aimed to quantify the short
term and long term psychological impact of primary
care based stepwise screening for type 2 diabetes.7 Spe-
cifically, the psychological impact study aimed to
examine the direct harms or benefits to screening
attenders in terms of anxiety and depression,7 10 and
to investigate the indirect harms caused by false reas-
surance (the focus of this paper). The psychological
impact study was a controlled trial comparing screen-
ing attenders (n=4370) from 10 screening practices
with controls (n=964) from five practices whose
patients were not invited to screening; the primary
comparison to test for false reassurance is between
those who test negative for diabetes at screening and
(non-screened) controls. The figure shows thedesign of
this study and the flow of participants through the
screening programme.
In the 10 screening practices, patients aged
40-69 years identified by the Cambridge diabetes risk
score as being in the top quarter of risk of having
undiagnosed diabetes (n=6416) were invited to attend
a stepwise diabetes screening programme.24 The step-
wise screening programme has been described
previously.4 7 The invitation letter informed patients
that “from the information in your medical records
you have been identified as being at risk of having
undiagnosed diabetes,” and invited them to attend a
random capillary blood glucose test in general prac-
tice. People who tested positive at this initial test
(n=1787) were told: “According to this test, you have
about a 15-20% chance of having diabetes. In order to
find out for certain whether you have diabetes or not,
weneed to do further tests.”Participantswith a random
blood glucose of 5.5 mmol/l or more were invited to
return on a different day for a fasting capillary blood
Attended random glucose test (n=4370)
Screened negative (n=2583) 
Responders: 81%, 67%, 67%
Attended fasting glucose test (n=1658)
Screened negative (n=1297)
Responders: 67%, 72%, 69%
Attended oral glucose tolerance test (n=296)
Screened negative (n=146)
Responders: 67%, 72%, 78%
Screened positive: newly diagnosed diabetes (n=150)
Responders: 66%, 74%, 75%
Control participants (n=964)
Control group A (n=484)
Responders: 54%, 43%, 37%
Control group B (n=480)
Responders: N/A, 50%, 43%
Screened positive (n=1787)
Did not attend subsequent tests (n=129)
Screened positive (n=361)
Did not attend subsequent tests (n=65)
Flow of participants through screening programme, with
questionnaire response rates at each time point (after initial
appointment, 3-6 months later, 12-15 months later)
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glucose test. People who tested positive at the fasting
blood glucose test were told: “This test result does sug-
gest that you have diabetes, but a diagnosis of diabetes
is for life, so it is very important that we make abso-
lutely sure that you have the condition. To confirm
diagnosis of diabetes youwill need tomake an appoint-
ment for a blood test at a local hospital.” Those with
either a fasting blood glucose of 6.1mmol/l or above, a
fasting blood glucose of 5.5-6.1 mmol/l and a glycated
haemoglobin of 6.1% or more, or a random blood glu-
cose of 11.1mmol/l or abovewere invited to attend for
a standard 75 g oral glucose tolerance test at an out-
patient centre. Diagnosis of type 2 diabetes was made
according to the World Health Organization’s
criteria.25 Participants who tested negative for diabetes
at any stage in the stepwise screening programmewere
told: “This test is normal; you do not have diabetes.”
In the screening practices, patients who attended for
the initial test (n=4370) were given a questionnaire to
complete and return by mail to the research centre.
Questionnaire data from this time point (time 1) repre-
sent participants’ views after the initial test when they
had been informed either that they did not have dia-
betes (screened negative) or that they needed further
tests (screened positive). Follow-up questionnaires
were sent three to six months (time 2) and
12-15 months (time 3) after the initial test.
In the five control practices, a 25% randomsample of
participants identified as being in the top quarter of risk
(n=964) were randomly allocated to two groups (A and
B). Group A (n=484) were sent questionnaires at three
time points equivalent to those for participants in the
screening practices, and group B (n=480) received
questionnaires at times 2 and 3 only—for a substudy
investigating measurement effects.26 The letter accom-
panying the questionnaire informed control partici-
pants that “some people of your age can have
diabetes without realising it.”
Consent to participate in thequestionnaire studywas
obtained during attendance at the initial test; control
participants received an information sheet and consent
form from their practice with their first questionnaire.
At each timepoint, participantswhohadnot returned a
questionnaire after approximately three weeks were
sent one reminder (including another copy of the ques-
tionnaire).
Outcome measures
Perceived personal risk—Participants were asked to esti-
mate their chance of getting diabetes at some time in
their life. Responses were given as a percentage score
on an 11 point scale ranging from 0% to 100%.
Perceived comparative risk—Participants were asked to
indicate their chance of getting diabetes, compared
with other people of their age. Response options pro-
vided on a five point rating scale were (1) much lower,
(2) a little lower, (3) about the same, (4) a little higher,
and (5) much higher.27
Behavioural intention—Participants were asked to rate
three statements of intention to be more physically
active, to eat a lower fat diet, and to reduce the amount
of dietary sugar in the next 12 months. Response
options provided on a five point rating scale were (1)
strongly disagree, (2) disagree, (3) neither agree nor
disagree, (4) agree, and (5) strongly agree.
Self rated health—A single item asked about the parti-
cipant’s general health, with response options of (1)
excellent, (2) very good, (3) good, (4) fair, and (5) poor.
Sample size
We determined the sample size in a previous substudy
to quantify the effects of screening on anxiety and
depression.7 The observed 95% confidence interval
for the primary outcome, personal risk, in this study
incorporates the observed clustering of the outcome
by practice and provides the basis of an indicative
post hoc calculation of detectable effect sizes. We
would have 80% power to detect a difference between
screened and control groups in mean personal risk of
6.5 scale units at baseline (standardised difference of
0.30 SD) and 5.75 units at later time points (equivalent
to effect size differences of 0.3 SD and 0.27 SD).
Analyses
We first explored differences in the demographic and
clinical characteristics of control group participants
and screening attenders (and also those who screened
negative) by using analysis of variance and χ2 tests.We
used χ2 tests to assess differences between question-
naire responders and non-responders. Primary ana-
lyses used a linear mixed effects model to compare
participants who screened negative for diabetes with
controls on outcome measures at the initial time point
and at three to six months and 12-15 months after
screening. Because allocation of participants to groups
for the controlled trial was practice based,47 we entered
practice as a randomeffect in allmultivariatemodels to
account for potential clustering. We assessed hypoth-
eses by using two sided tests at the 5% level of signifi-
cance. Firstly, we assessed differences in perceived
risk, behavioural intentions, and self rated health at
time 1betweenpeoplewho screenednegative and con-
trols. Secondly, we assessed differences in perceived
risk, behavioural intentions, and self rated health
between four screening subgroups and controls at
times 2 and 3. To further examine the effect of progress
through a stepwise screening programme, we used lin-
ear regression analysis to examine the relationbetween
number of screening and diagnostic tests and per-
ceived risk among people who screened negative for
diabetes.
RESULTS
Of 6416 people invited to screening, 68% (n=4370)
attended the initial random capillary blood glucose
test in general practice. Among the screening atten-
ders, 82% (n=1465) of 1787 screen positives and 81%
(n=2092) of 2583 screen negatives returned a com-
pleted questionnaire after their first appointment.
Removal of 310 questionnaires from people who
screened positive that were returned late (after the
date of a follow-up fasting capillary blood glucose test
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or oral glucose tolerance test) gives an amended
response rate of 65% (n=1162) for the screen positive
group.Control group response rateswere 54% (n=261)
at the first contact point, 47% (n=454) at three to six
months, and 40% (n=386) at 12-15 months. The figure
shows the flow of participants through the screening
programme and the questionnaire response rates at
each time point.
We found no significant differences between con-
trols and screening attenders in terms of age, sex,
body mass index, diabetes risk score, or prescription
of antihypertensive drugs at baseline (table 1). No sig-
nificant differences in baseline data existed between
controls and people who screened negative at the
initial test (table 1). Overall, at time 1, self rated health
was high and intentions to change behaviour were
modest: 77% of participants rated their health as
good, very good, or excellent; 61% intended to reduce
their dietary fat; and 54% intended to increase their
levels of physical activity.
Immediate impact of initial screening result
Planned comparisons showed no statistically signifi-
cant differences in mean scores for the three beha-
vioural intention variables, self rated health, or
perceived personal risk between controls and people
screening negative at time 1 (table 2). People who
screened negative for diabetes at the initial test
reported a slightly lower perceived comparative risk
of developing diabetes in the future than did control
participants (mean difference −0.16, 95% confidence
interval −0.30 to −0.02; P=0.04) (table 2).
Longer term impact of screening results
Planned comparisons between controls and people
who screened negative showed no evidence of false
reassurance. No differences existed between controls
andpeoplewho screenednegative for perceived risk or
behavioural intention variables at three to six or
12-15 months after the initial screening appointment
(table 3).
Effect of progress through stepwise screening programme
Progress through the stepwise screening programme
was associated with higher mean perceived personal
and comparative risk of developing diabetes. We
found a significant linear trend in mean scores for per-
ceived personal risk at time 2 (P<0.001) and time 3
(P=0.001) and for perceived comparative risk at time
3 (<0.001) across the three screen negative subgroups
(table 3).
Comparison of responders and non-responders
Non-responders to the initial questionnaire in both the
screening and control groupswere likely to be younger
(mean age 56) than responders (mean age 59) andmore
likely to bemale (70% v 61%) but were comparable for
body mass index, diabetes risk score, and prescribed
antihypertensive drugs. Sensitivity analyses to further
investigate potential bias arising from non-response to
the questionnaire showed that non-responders in the
screen negative group would have had to report a
mean perceived personal risk at least 10.5 units (on a
scale from 0% to 100%) lower than their responding
counterparts to affect the conclusions of our study in
relation to false reassurance.
DISCUSSION
Our results showvery limited evidence of false reassur-
ance among people who received a negative test result
after attending screening for diabetes. In the short
term, those who screened negative at the initial test
did not report a lower perceived personal risk of devel-
oping diabetes or lower intentions for behavioural
change than a non-screening control group. They
reported a lower perceived comparative risk of devel-
oping diabetes, but the difference was very small. We
found no evidence of false reassurance in the medium
to long term; people who screened negative did not
report a lower perceived risk of diabetes or lower inten-
tions for behavioural change than the control group at
three to six or 12-15 months after the initial test. The
findings suggest that the process of attending a primary
care based stepwise diabetes screening programme
would be unlikely to lead to an adverse shift in the
population distribution of plasma glucose and cardio-
vascular risk as a result of an increase in unhealthy
behaviours arising from false reassurance among peo-
ple who screen negative.
Variations in the process and context of a screening
programme may influence perceptions of residual
risk.10 In terms of the number of tests needed, an
Table 1 | Baseline demographic and clinical characteristics of control group, screening attenders, and people who screened negative in initial test. Values are
means (SD) unless stated otherwise
Demographic and clinical
variables Control group (n=964)
Screening attenders
(n=4370)
P values* for group
differences†
Screened negative at initial
test (n=2583)
P values* for group
differences‡
Age 58.6 (7.8) 58.7 (7.6) 0.76 58.1 (7.6) 0.63
No (%) female 343 (36) 1629 (37) 0.42 993 (38) 0.22
Body mass index (kg/m2) 30.6 (4.9) (n=887) 30.3 (4.5) (n=4027) 0.38 30.3 (4.4) (n=2376) 0.37
Cambridge diabetes risk score 0.41 (0.19) (n=886) 0.41 (0.19) (n=4027) 0.65 0.40 (0.19) (n=2376) 0.19
No (%) prescribed
antihypertensive drugs
472 (49) 2141 (49) 0.83 1201 (47) 0.47
*χ2 tests and univariate (analysis of variance) tests for group differences.
†Comparing control group and screening attenders.
‡Comparing control group and people who screened negative at initial random blood glucose test.
RESEARCH
page 4 of 7 BMJ | ONLINE FIRST | bmj.com
inadequate or ambiguous test result has been asso-
ciated with psychological costs including increased
anxiety in a cervical screening programme.28Our find-
ings show a linear trend of increasing perceived risk
associated with progression through the different tests
involved in the screening programme.However, this is
mainly explained by the much higher perceived risk
among people who tested negative at the final diagnos-
tic test, compared with the two groups who screened
negative at the earlier tests. This may be because the
earlier practice based tests were done by a known prac-
tice nurse in familiar surroundings compared with the
unfamiliarity of the hospital outpatient context of the
final test.
Strengths and limitations
The large sample size in this study enabled examina-
tion of subgroups of participants who screened nega-
tive at different stages in the screening programme.
The prospective research design allowed investigation
of false reassurance in the short, medium, and longer
term. Inclusion of a control group enabled investiga-
tion of the impact of a negative test result alone, as
opposed to in comparison with a positive result.
Embedding the studywithin theADDITION trial pro-
vided a real world setting.
The study has some limitations. No operational defi-
nition of false reassurance has been agreed; in this
paper we define the construct in terms of perceived
risk, behavioural intentions, and self rated health.
Room for improvement in assessing participants’
interpretation of their negative test result exists—in
particular, how it will change their behaviour or be
taken as “proof that they did not need to change their
way of life.”16 As noted earlier, and previously,7 10 the
stepwise nature of the screening programme is likely to
evoke different psychological responses from other
types of diabetes screening being considered,29 thus
altering the generalisability of our findings.
We acknowledge the low relative response rates to
the questionnaire survey among control participants
(54%, 47%, and 40% at first contact point, three to six
months, and 12-15 months) and possible selection bias
among people who chose to respond to the invitation
to screening as limitations in this study. However, little
evidence of bias owing to non-response affecting the
comparability of the control and screening groups
exists; our results show no differences in terms of
demographic or clinical characteristics at baseline
between controls and screening attenders or between
controls and people who screened negative at the
initial random blood glucose test. Sensitivity analyses
showed that if non-responders had reported lower per-
ceived risk than questionnaire responders the effect
would be to lower perceived risk in the control group
and to further reduce the evidence in favour of false
reassurance among those who test negative for dia-
betes. Non-responders in the screen negative group
would have to report a mean perceived personal risk
of diabetes at least 10% (10.5 units on a scale from0% to
100%) lower than their responding counterparts to
affect the conclusions of our study in relation to false
reassurance.
Our finding that false reassurance among those who
screen negative is minimal and dissipates with time
concurs with evidence from a systematic review.14 It
integrates previous findings by showing a short term
effect, in common with other studies,17 28 but no long
term effect, in keeping with research showing the
diminished effects of false reassurance over time.30
Differences in the research design and the measure-
ment of false reassurance may help to explain the var-
iation across studies. For example, false reassurance
seems most likely in cross sectional research and in
studies that quantify false reassurance in terms of the
patient’s understanding of a “normal” test result.17 30 31
As noted earlier, variations in the context of screening
programmes may also influence whether patients are
falsely reassured. A stepwise primary care based
screening programmemayminimise false reassurance
because it offersmultiple points of contact between the
patient and health professionals and, therefore,
ongoing opportunities to clarify themeaning of a nega-
tive test result both within the screening programme
and in primary care after screening. False reassurance
seems to bemore common in certain types of screening
programmes, such as those testing for cervical
cancer,28 30 perhaps because a substantial proportion
of screening attenders report that they do not under-
stand the meaning of their test result.17
Participants’ interpretation of their screening test
results is likely to be influenced by the explanation
Table 2 | Differences in psychological variables between screening attenders and control participants at initial time point*. Values are means (SD) unless
stated otherwise
Psychological variables
Control group A,
non-screening
Screened negative at initial
(random blood glucose) test
Screened positive at initial test
and referred for further testing
Difference† (95% CI);
P value
Personal risk 31.5 (22.7) (n=251) 29.9 (20.8) (n=1994) 34.9 (22.2) (n=1079) −1.58 (−4.79 to 1.65); 0.35
Comparative risk 2.92 (0.97) (n=254) 2.76 (1.02) (n=2013) 3.04 (0.95) (n=1106) −0.16 (−0.30 to −0.02); 0.044
Intention to reduce dietary fat 3.63 (0.96) (n=260) 3.67 (0.88) (n=2065) 3.58 (0.89) (n=1140) 0.04 (−0.08 to 0.17); 0.52
Intention to reduce dietary sugar 3.54 (1.01) (n=260) 3.58 (0.92) (n=2058) 3.52 (0.91) (n=1148) 0.04 (−0.09 to 0.17); 0.54
Intention to increase exercise 3.48 (0.94) (n=261) 3.58 (0.87) (n=2065) 3.49 (0.87) (n=1138) 0.10 (−0.02 to 0.21); 0.11
Self rated health 3.14 (0.85) (n=253) 3.17 (0.87) (n=2056) 2.97 (0.89) (n=1142) 0.02 (−0.15 to 0.19); 0.83
*Immediately after initial (random blood glucose) test for screening attenders; first contact for control participants.
†Screen negative group minus control group.
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given by the healthcare professional doing the test.21 A
qualitative paper that reports patients’ experiences of
screening for type 2 diabetes in the ADDITION study
indicates that many of those who test negative at dia-
betes screening seem to be unaware of their residual
risk of diabetes10; this suggests that the explanation of
the results of screening tests could be improved. To
maximise the potential benefits of diabetes screening
programmes, the explanation of a negative test result
could convey both the residual risk of diabetes and that
ways exist to reduce this risk through behavioural
change.
Directions for future research:
Considering the limitations outlined, theoretical devel-
opment is needed to generate a shared understanding
of false reassurance—in terms of both the psychologi-
cal and behavioural meanings and to whom it applies
—and thus an agreed operational definition. Further-
more, a measure, preferably objective, of actual beha-
viour rather than intentions would enable future
research to assess the behavioural consequences of
false reassurance.
Targeted screening programmes such as ADDI-
TION need to ensure that people who screen negative
(at any stage in the series of tests) do notmisunderstand
the meaning of their test result. Screening negative
does not mean no risk of diabetes; rather, for this
group (those identified as having risk factors for devel-
oping diabetes by use of a risk score), it means “low
risk” of having diabetes now but increased risk of
developing diabetes and related adverse health out-
comes in the future. Research into cervical screening
found that 20% of women with an inadequate result
followed by a normal repeat smear failed to appreciate
their residual risk.30We find it promising therefore that
our study participants who progressed the furthest
through the tests before screening negative perceived
higher personal risk than those who screened negative
at earlier tests. Research to establish the most effective
ways of communicating screening test results and resi-
dual risks would be helpful.
Implications for population health
Although some studies have suggested that screening
programmes could interfere with population strategies
that aim to reduce heart disease,22 little evidence shows
that implementing a primary care based stepwise
screening programme for diabetes (based on the
ADDITION (Cambridge) trial) would have a negative
net effect on intentions to increase physical activity or
to reduce dietary fat and sugar in the screened popula-
tion.
Implications for diabetes screening
Screening for diabetes is now under way within the
vascular risk assessment programme, but debate con-
tinues as to when and how to do this screening.2 3 23 29 A
key criterion for the justification of screening pro-
grammes is that the overall benefit of testing the popu-
lation is greater than any possible harms,3 so
arguments for screening for diabetes should be
Table 3 | Differences in psychological variables between screening attenders and control participants after 3-6 months* and 12-15 months* of follow-up.
Values are mean (SD) unless stated otherwise
Psychological
variables and
time
Control (group A
+B), non-screening Screened negative
Difference† (95% CI); P
value
Screened negative at
random blood
glucose test
Screened negative
at fasting blood
glucose test
Screened negative
at oral glucose
tolerance test
Screened positive at
oral glucose
tolerance test
Personal risk
3-6 months 31.7 (21.2) (n=418) 31.5 (21.0) (n=2195) −0.45 (−3.28 to 2.39); 0.76 30.9 (20.8) (n=1487) 31.7 (20.4) (n=631) 44.2 (25.9) (n=77) NA‡
12-15 months 32.8 (20.7) (n=362) 32.2 (21.4) (n=2186) −0.78 (−3.91 to 2.35); 0.63 31.6 (21.1) (n=1469) 32.2 (21.0) (n=631) 42.6 (26.5) (n=86) NA‡
Comparative risk
3-6 months 2.86 (0.94) (n=426) 2.84 (0.95) (n=2238) −0.02 (−0.13 to 0.09); 0.74 2.83 (0.94) (n=1516) 2.82 (0.93) (n=644) 3.23 (1.18) (n=78) NA‡
12-15 months 2.95 (0.95) (n=369) 2.85 (0.96) (n=2222) −0.11 (−0.21 to 0); 0.068 2.80 (0.96) (n=1495) 2.91 (0.94) (n=639) 3.16 (1.03) (n=88) NA‡
Intention to reduce dietary fat
3-6 months 3.68 (0.84) (n=448) 3.70 (0.87) (n=2294) 0.01 (−0.07 to 0.10); 0.75 3.69 (0.85) (n=1551) 3.68 (0.89) (n=661) 3.95 (0.86) (n=82) 4.10 (0.70) (n=80)
12-15 months 3.68 (0.85) (n=385) 3.66 (0.86) (n=2292) −0.01 (−0.10 to 0.08); 0.83 3.70 (0.86) (n=1541) 3.59 (0.87) (n=662) 3.72 (0.69) (n=89) 4.03 (0.79) (n=78)
Intention to reduce dietary sugar
3-6 months 3.58 (0.91) (n=447) 3.60 (0.91) (n=2284) 0.02 (−0.07 to 0.12); 0.67 3.59 (0.90) (n=1543) 3.60 (0.92) (n=659) 3.83 (0.94) (n=82) 4.28 (0.75) (n=80)
12-15 months 3.58 (0.88) (n=383) 3.60 (0.92) (n=2291) 0.02 (−0.08 to 0.12); 0.70 3.62 (0.92) (n=1542) 3.54 (0.92) (n=661) 3.72 (0.79) (n=88) 4.19 (0.97) (n=78)
Intention to increase exercise
3-6 months 3.60 (0.81) (n=447) 3.56 (0.82) (n=2288) −0.04 (−0.14 to 0.06); 0.48 3.59 (0.82) (n=1550) 3.49 (0.84) (n=656) 3.65 (0.82) (n=82) 3.81 (0.71) (n=80)
12-15 months 3.53 (0.87) (n=385) 3.55 (0.84) (n=2293) 0.03 (−0.08 to 0.14); 0.62 3.59 (0.84) (n=1541) 3.48 (0.84) (n=663) 3.49 (0.84) (n=89) 3.56 (0.85) (n=78)
Self-rated health
3-6 months 3.14 (0.80) (n=443) 3.14 (0.87) (n=2287) 0.01 (−0.15 to 0.16); 0.94 3.17 (0.86) (n=1553) 3.09 (0.88) (n=654) 2.98 (0.93) (n=80) 2.97 (0.85) (n=78)
12-15 months 3.21 (0.81) (n=383) 3.16 (0.86) (n=2284) −0.05 (−0.21 to 0.11); 0.53 3.19 (0.85) (n=1533) 3.12 (0.87) (n=662) 3.04 (0.84) (n=89) 3.12 (0.82) (n=78)
NA=not applicable.
*Time since initial random blood glucose test for screening groups; time since first contact for control group.
†Screen negative group minus control group.
‡Participants who screened positive at oral glucose tolerance test were not asked about their perceived risk of getting diabetes at follow-up time points.
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evidence based and contextualisedwithin a framework
that weighs up the benefits versus harms of screening.
Research shows limited evidenceof harms to screening
attenders, either from increased anxiety or depression
or from false reassurance among those who receive a
negative result at screening (this paper).7-9 Further-
more, evidence is growing of the benefits of screening;
for example, stepwise screening identifies people with
a raised and potentially modifiable risk of coronary
heart disease.5 This study adds to accumulating evi-
dence showing that the overall benefit of widespread
testing is likely to be greater than the possible harms to
the population, and this suggests that justification of
screening for diabetes is becoming less “uncertain.”3
However, important questions still remain concerning
the cost effectiveness of widespread screening.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Screening for type 2 diabetes does not seem to have an adverse psychological impact in
terms of increased anxiety and depression
The potential adverse effects of false reassurance among people who test negative for
diabetes at screening are unknown; no evidence is available from controlled trials
WHAT THIS STUDY ADDS
A negative test result at diabetes screening does not seem to promote false reassurance
Primary care based stepwise screening for diabetes is unlikely to cause an adverse shift in
risk perceptions, health related behaviours, or the population distribution of plasma glucose
and cardiovascular risk
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 7
